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Psoriasis was until recently regarded as a T-cell-driven
disease with presumed (auto)immune mechanisms as
its primary cause. This view was supported by clinical
data and genetic studies that identified risk factors
functioning in adaptive and innate immunity, such
as HLA-C*06, ERAP1, the IL-23 pathway, and NF-kB
signaling. Candidate gene approaches and genome-
wide association studies, however, have identified
copy number polymorphisms of the b-defensin cluster
and deletion of late cornified envelope (LCE) 3B and
3C genes (LCE3C_LCE3B-del) as psoriasis risk factors.
As these genes are expressed in epithelial cells and
not by the immune system, these findings may cause a
change of paradigm for psoriasis, not unlike the reported
filaggrin association that has profoundly changed the
views on atopic dermatitis. In addition to genetic
polymorphisms of the immune system, genetic varia-
tions affecting the skin barrier are likely to contribute
to psoriasis. Recent studies have shown epistatic
interactions involving HLA-C*06, ERAP1, and LCE3C_
LCE3B-del, which makes psoriasis a unique model
to investigate genetic and biological interactions of
associated genes in a complex disease. We present a
model for disease initiation and perpetuation, which
integrates the available genetic, immunobiological,
and clinical data.
Journal of Investigative Dermatology (2012) 132, 2320–2331;
doi:10.1038/jid.2012.167; published online 24 May 2012
INTRODUCTION
Psoriasis: epidermal versus immune pathogenesis
Psoriasis is a common inflammatory skin disease that has
both genetic and environmental factors to its etiology. For an
in-depth overview of clinical aspects and immunobiology of
psoriasis, we refer to several excellent reviews on this subject
(Bowcock and Krueger, 2005; Schon and Boehncke, 2005;
Nestle et al., 2009). The question whether psoriasis is an
epithelial disease or an immune-mediated disease has gene-
rated considerable debate over the past decades, but remains
essentially unresolved. Until the early 1980s, psoriasis was
considered to be a keratinocyte disease, but the advent of
cyclosporin A as an effective mechanism-based treatment has
changed this (Ellis et al., 1986). For the past three decades,
psoriasis was primarily regarded as an immune-mediated
disease, although the pendulum has begun to swing back
lately (Nickoloff, 2006). The concept of an (auto)immune basis
is supported by the presence of activated T cells and other
immunocompetent cells in psoriatic lesions and the efficacy
of T-cell-targeted therapeutics, such as cyclosporin A, DAB389IL-
2, alefacept, and efaluzimab (Lowes et al., 2007). Other
circumstantial evidence for an immune-based pathogenesis
stems from genetic data (discussed below) and antipsoriatic
therapies that are thought to target the adaptive immune
system rather than the epidermis (corticosteroids, UVB,
fumarates; Schwarz, 2008). Animal models involving xeno-
graft transplantation provide further evidence for an immune-
mediated pathogenesis. In these experiments, grafts of human
uninvolved psoriatic skin onto severe combined immuno-
deficient mice can develop into lesional psoriatic skin by direct
injection of activated T cells from the donor (Wrone-Smith
and Nickoloff, 1996). In addition, a psoriatic phenotype can
develop by expansion of resident T cells of grafted non-lesional
skin (Boyman et al., 2004). Although it is clear that participation
of cell types non-intrinsic to the skin is mandatory for the
development of psoriatic lesions, none of these animal models
excludes a contribution of the epidermal keratinocytes.
Various studies have documented skin barrier abnormal-
ities in psoriasis, but genes involved in keratinocyte differen-
tiation, with the exception of corneodesmosin (CDSN), have
not been considered as genetic risk factors until recently.
Here we review data from genetic studies and provide an
overview of all currently known risk factors. Copy number
variation (CNV) of genes involved in the chemical and
physical skin barrier found to be associated with psoriasis are
discussed in detail.
Genetics of psoriasis
A strong genetic basis for psoriasis has been firmly establi-
shed in many epidemiological and genetic studies for which
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many excellent reviews are available (Capon et al., 2004b,
2012; Bowcock and Krueger, 2005; Gudjonsson and Elder,
2007). Twin studies showed a concordance rate of 35–72% in
monozygotic twins, and 12–35% in dizygotic twins. About
70% of the patients with childhood psoriasis report a positive
family history (Morris et al., 2001). In the past decades,
several linkage studies (Tomfohrde et al., 1994; Nair et al.,
1997; Capon et al., 1999a) and, more recently, genome-wide
association studies (GWASs) have been conducted to find
susceptibility loci for psoriasis (Cargill et al., 2007; Capon
et al., 2008; Liu et al., 2008; Nair et al., 2009; Zhang et al.,
2009; Ellinghaus et al., 2010; Strange et al., 2010; Stuart
et al., 2010; Sun et al., 2010; Huffmeier et al., 2010b).
Linkage analysis has identified at least nine loci and have
been designated PSORS1 to PSORS9. GWASs and candidate
gene approaches have now identified over 20 psoriasis loci.
Several, albeit not all of them, have been confirmed by
studies in various populations. All performed GWASs for
psoriasis, however, show associations with the PSORS1
region. Furthermore, each scan finds its own new regions,
but these are often difficult to validate in an independent data
set (Capon et al., 2004b). For most of these loci, single-
nucleotide polymorphisms (SNPs) have been identified in or
near candidate genes, but convincing evidence for causative
mutations that clearly define a mechanistic basis is largely
lacking. Despite these difficulties, genetic studies are a useful
source of knowledge and can provide new insights into the
pathogenesis of psoriasis, as recently reviewed by Capon
et al. (2012).
The strongest and invariably reproduced susceptibility
locus, PSORS1, harbors HLA-C*06, which was already known
to be associated with psoriasis in the 1970s. This locus
contains several genes including CDSN, which encodes a
protein expressed in differentiated keratinocytes. However,
because of linkage disequilibrium, the tendency of two genes
to be inherited together more often than would be predicted
by chance, it is difficult to identify the true causative sus-
ceptibility gene of the PSORS1 locus. Studies of Orru et al.
(2005) suggest that the CDSN is the susceptibility gene,
whereas Nair et al. (2006) reported that HLA-C*06 is the most
likely susceptibility gene in the PSORS1 region. Alternatively,
it might even be possible that both HLA-C*06 and CDSN
contribute to psoriasis susceptibility (Capon et al., 2004b).
Given its role in antigen presentation, the association with
HLA-C*06 strongly points at a role of the adaptive immune
system in psoriasis. Although the PSORS1 region is the most
replicated and best-known susceptibility locus for psoriasis,
it accounts for less than 50% of the familial aggregation
(estimated population attributable risk: 29%, based on
frequency of HLA-C*06 in control population 0.17 and odds
ratio of 3.45 (Riveira-Munoz et al., 2011)). Therefore, other
loci must contribute to the pathogenesis of psoriasis. Recent,
widely replicated associations comprise SNPs mapped near
the IL-12B gene, coding for the p40 subunit of IL-12 and near
a subunit of the IL-23 receptor (Tsunemi et al., 2002; Capon
et al., 2007; Cargill et al., 2007). In several other large-scale
GWASs (Capon et al., 2008; Liu et al., 2008; Nair et al.,
2009; Zhang et al., 2009; Ellinghaus et al., 2010; Strange
et al., 2010; Stuart et al., 2010; Sun et al., 2010; Huffmeier
et al., 2010b) many of these associations were confirmed,
and additionally many new SNPs were reported to be
associated with psoriasis. Several of these new SNPs were
found in or near genes associated with the adaptive or innate
immune system such as IL23A, TNFAIP3 (tumor necrosis factor
(TNF)-a induced protein 3), TNIP1 (TNFAIP3-interacting
protein 1), IL-4, and IL-13. Table 1 lists the known replicated
genetic associations with psoriasis to date.
Although most of the available genetic and clinical data
at this point supported a role of T-cell-driven processes,
epidermis-expressed genes could not be completely ruled
out. For example, cell biological studies suggest that kera-
tinocytes of psoriatic patients, and also from atopic dermatitis
patients, are intrinsically different from control keratinocytes.
Cultured keratinocytes from patients react differently to
stimuli such as cytokines, most likely because of genetically
programmed differences (Giustizieri et al., 2001; Zeeuwen
et al., 2008). The recent finding that filaggrin is a major gene
in atopic dermatitis, a disease thought to be primarily driven
by the immune system, provided a shift of paradigm,
indicating that we should consider similar mechanisms in
psoriasis as well. Two studies have recently identified regions
in the human genome that are subject to CNV and are
associated with psoriasis. CNV of a genomic segment on
chromosome 8p23.1 harboring a cluster of DEFB genes,
encoding the b-defensins, and a CNV in the PSORS4 region
on chromosome 1q21, specifically the deletion of late
cornified envelope (LCE)3B and LCE3C, were found to be
associated with psoriasis. Remarkably, these newly asso-
ciated genes are expressed in the epidermis and not in
immunocytes (see Figures 1 and 2), as will be discussed
below.
b-Defensins and psoriasis
b-Defensins are small antimicrobial peptides that possess a
broad spectrum of antimicrobial activity against both Gram-
positive and Gram-negative bacteria, as well as fungi and
viruses (Schroder and Harder, 1999; Ganz, 2003). Because of
their antimicrobial activity, the b-defensins, together with
other antimicrobial peptides, are likely to be responsible
for the chemical barrier and innate immunity of the skin.
This idea is supported by observations in inflammatory skin
diseases such as psoriasis and atopic dermatitis. Atopic
dermatitis is associated with a high prevalence of skin
infections, whereas infections are rare in psoriasis (Christo-
phers and Henseler, 1987). This could be explained by
reduced mRNA and protein levels of antimicrobial proteins
(e.g., hBD-2, hBD-3, elafin, and LL-37) in atopic dermatitis as
compared with psoriasis (Ong et al., 2002; de Jongh et al.,
2005). When comparing the expression of hBD-1, 2, and 3 in
normal skin and in psoriasis and atopic dermatitis patients, it
was shown that hBD-2 is by far the most upregulated
b-defensin in lesional psoriatic skin and can be used as a
serum biomarker for disease activity (Figure 1 panel DEFB4,
Figure 2a; Jansen et al., 2009).
Besides antimicrobial activity, b-defensins also exhibit
proinflammatory properties as chemoattractants for immune
www.jidonline.org 2321
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cells, such as immature dendritic cells, memory T cells, TNF-
a-treated neutrophils, and mast cells (Yang et al., 1999, 2002;
Niyonsaba et al., 2002, 2004). Because of these properties,
b-defensins provide a link between the innate and adaptive
immune system.
The genes coding for the b-defensins are located on
chromosome 8p23.1 of the human genome. In this region,
seven b-defensin genes are located. Six of these genes,
including DEFB4 (encoding hBD-2) and DEFB103 (encoding
hBD-3), are localized on a very large repeat unit that can vary
in copy number. DEFB1 (encoding the protein hBD-1) is not
localized on this repeat and therefore not subject to CNV
(Hollox et al., 2003). In humans, up to 12 copies of this repeat
have been found, with a mode of four copies per diploid
genome (Hollox et al., 2008). On the basis of the functional
data on b-defensins (particularly hBD-2) and psoriasis, we
hypothesized that the CNV of the b-defensin cluster on
8p23.1 could be associated with psoriasis. Analysis of the
b-defensin cluster in a Dutch and German case–control
cohort showed indeed a significant association between
higher genomic copy number and the risk of psoriasis
(Hollox et al., 2008). This finding has recently been
replicated in a large independent cohort, although the
association was weaker than that of the initial study (Stuart
et al., in press). As six b-defensin genes are part of the
repeat region and show the same CNV, we were not able
to distinguish whether one gene or a combination of all
b-defensins is responsible for the association with psor-
iasis. Altogether, these data indicate that the b-defensins,
produced in keratinocytes, could have a role in the
pathophysiology of psoriasis.
The mechanism, however, by which increased defensin
genomic copy number predisposes to psoriasis is currently
unknown. We presume that a high copy number of the
b-defensin cluster on 8p23.1 provides increased b-defensin
protein production. In a recent study, we could demonstrate
that there is indeed a significant, albeit moderate, correlation
between genomic copy number and serum hBD-2 levels in
healthy controls (Jansen et al., 2009). Speculatively, increased
cutaneous b-defensin production could provide increased
protection against infection upon skin barrier disruption. This
evolutionary benefit may have promoted the frequency of
DEFB4
Psoriasis skin
Normal skin
Blood
Spleen
Pharynx
Gingiva
Tongue
0.01 0.1 1 10 100 0.1 1 10 100 1010.10.011,000 100
Relative quantity
Lymph node
LCE2B LCE3A
Figure 1. DEFB4 and LCE genes are mainly expressed in skin. Relative mRNA expression levels of DEFB4, LCE2B, and LCE3A in normal and psoriasis skin,
several immune-associated tissues, and oral human tissues. Expression of target genes was normalized to that of RPLP0. For graphic representation, per gene
values are expressed relative to expression in tongue, which was set at unity, to enable comparison of expression between tissues (see Livak and Schmittgen
(2001)). LCE data reprinted from Bergboer et al. (2011), with permission from Elsevier. DEFB4 data reprinted from Jansen et al. (2009).
St
ra
tu
m
 g
ra
nu
lo
su
m
st
ra
tu
m
 c
or
ne
um
Figure 2. hBD-2 and LCE2 protein expression in skin. (a) hBD-2 protein expression in normal skin (left) and in involved psoriasis skin (right). In normal skin
hBD-2 is not expressed, and in involved psoriasis skin hBD-2 expression is heavily induced, bar¼ 100mm. (b) LCE2 protein expression in normal skin assessed
by immunoelectron microscopy. Arrows indicate gold-labeled LCE2 antibodies that stain the cornified envelope structure in normal skin, bar¼200 nm.
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chromosomes carrying higher b-defensin copy numbers. As
the defensins are also chemotactic for inflammatory cells,
high copy numbers may also increase the propensity to
mount a vigorous inflammatory response to minor stimuli.
These properties of b-defensins may be two sides of the same
coin, leading to an evolutionary advantage for carriers of high
defensin copy numbers at the expense of an increased risk for
psoriasis.
Structural epidermal proteins and psoriasis: the deletion of
LCE3B and LCE3C
Lesional psoriatic skin is characterized by premature kerati-
nocyte differentiation and defective keratinization, including
altered formation of the cornified envelope (CE). In psoriatic
skin, the components of the CE are differentially expressed
as compared with normal skin. Expression of the early
differentiation markers such as involucrin, CDSN, the small
proline-rich proteins, cystatin A, and transglutaminase 1 is
increased, whereas the expression of the late differentiation
markers such as loricrin and filaggrin is decreased (Ishida-
Yamamoto et al., 2000; Iizuka et al., 2004). The aberrant
formation of the CE affects the barrier capacity of the skin in
psoriasis. Several independent studies showed that transepi-
dermal water loss of lesional psoriatic skin is higher than the
transepidermal water loss of normal and uninvolved psoriatic
skin. Moreover, the level of the transepidermal water loss
is related to the clinical severity of the lesion, suggesting
that the barrier function of lesional psoriatic skin is
weaker than in normal skin (Grice et al., 1975; Motta
et al., 1994). The Koebner phenomenon, i.e., the appear-
ance of psoriatic lesions in uninvolved skin of psoriatic
patients as a consequence of superficial trauma, is another
indication for the involvement of the physical barrier
function of the skin (Powles et al., 1990). Although the
underlying molecular mechanism is not clear yet, the
keratinocytes may have a role in this phenomenon, either
by compromised barrier function or secretion of cytokines
(Wood et al., 1996).
In atopic dermatitis, until recently regarded as an immune-
mediated disease, the disrupted barrier function of the skin
is now considered a major cause of the disease. Loss-of-
function mutations in FLG (encoding the epidermis-specific
protein filaggrin) were shown to be associated with atopic
dermatitis in several populations (Palmer et al., 2006;
Rodriguez et al., 2009). As the FLG gene is located in or
near PSORS4, FLG mutations were also studied in psoriasis
patients, but no associations were found (Huffmeier et al.,
2007; Thyssen et al., 2011). The PSORS4 locus is positioned
on chromosome 1q21 in a region called the epidermal
differentiation complex (Mischke et al., 1996). The epidermal
differentiation complex is enriched for genes expressed
during epidermal differentiation, including loricrin (LOR),
involucrin (IVL), filaggrin (FLG), the small proline-rich protein
(SPRR) genes, and the LCE genes (Zhao and Elder, 1997;
Jackson et al., 2005). This last cluster, with a total of 18
members, is divided into six groups, LCE1-6, based on related
amino-acid sequences, genomic organization, and expres-
sion patterns (Jackson et al., 2005).
A study by de Cid et al. (2009) using array-comparative
genomic hybridization reported four regions on the human
genome subject to CNV that were potentially associated with
psoriasis in a Spanish cohort. Further investigations of one of
these regions demonstrated an association of a CNV in the
LCE cluster. A common deletion comprising the LCE3B and
LCE3C genes (LCE3C_LCE3B-del) was found with higher
frequency in patients compared with the controls. In this
study, a population attributable risk of 23% was found,
indicating that the deletion explains a sizable proportion of
the genetic contribution. The association with LCE3C_LCE3B-
del has been replicated in several cohorts with different
ethnic backgrounds (Huffmeier et al., 2010a; Li et al., 2011;
Riveira-Munoz et al., 2011; Xu et al., 2011). In addition, in an
independent GWAS of a large Chinese cohort, SNPs in strong
linkage disequilibrium with LCE3C_LCE3B-del were identi-
fied as risk factors for psoriasis (Zhang et al., 2009). In the
Dutch, American, and Chinese psoriasis cohorts, a genetic
interaction (epistasis) of LCE3C_LCE3B-del and HLA-C*06
was found (de Cid et al., 2009; Riveira-Munoz et al., 2011;
Zheng et al., 2011). A similar interaction between PSORS1
and PSORS4 was described previously by Capon et al.
(1999b) in an Italian cohort. Epistasis was less evident in
other cohorts studied (de Cid et al., 2009; Riveira-Munoz
et al., 2011), which might be due to heterogeneity between
populations. Until now, LCE3C_LCE3B-del was found to be
associated with psoriasis, psoriatic arthritis, and rheumatoid
arthritis in several populations (Bowes et al., 2010; Docampo
et al., 2010, 2011; Lu et al., 2011; Bergboer et al., 2012b),
whereas no association was found for atopic dermatitis
(Bergboer et al., 2010). In addition, in one study an asso-
ciation with systemic lupus erythematosus was found
(Lu et al., 2011), and in another study an association with
allergic contact dermatitis was detected (Molin et al., 2011),
implying that LCE3C_LCE3B-del may be a common risk
factor for inflammatory diseases.
To evaluate the possible function of the LCE3B and LCE3C
genes in psoriasis, de Cid et al. (2009) and Bergboer et al.
(2011) investigated the expression of almost all human LCE
genes. In a large tissue screen, moderate to high LCE
expression was largely confined to skin and a few orophar-
yngeal tissues (see Figure 1 panels LCE2B and LCE3A, and
Figure 2b). Jackson et al. (2005) showed that LCE1 and LCE2
group members are mainly expressed in skin, and they are
hardly expressed in internal epithelia. The LCE3 group members
are absent or variably expressed at low levels in internal and
external epithelia, and they show variable expression between
tissue types. LCE4 and LCE5 expression was barely detected
in the investigated tissues. The authors discovered hetero-
geneity between individuals with respect to the expres-
sion of the different LCE genes. Studies in cultured keratinocytes
showed that the LCE2 expression is induced by calcium, and
that UV induces the expression of the LCE1 and LCE2 groups
and of LCE3E.
The expression of LCE3 genes was hardly detectable in
normal and uninvolved psoriatic skin. In lesional psoriatic
skin, however, expression of the LCE3 genes (when present)
was highly induced (de Cid et al., 2009). In contrast,
www.jidonline.org 2325
JGM Bergboer et al.
Psoriasis: A Skin Barrier Disease?
expression of the members of other LCE groups was down-
regulated under these conditions. To investigate whether skin
barrier disruption might be a pathophysiological stimulus for
LCE3 expression, their expression was examined in healthy
individuals following minor skin injury by tape stripping.
Indeed, in normal skin, LCE3 gene expression was induced
upon tape stripping, whereas the genes of other LCE groups
were downregulated (Bergboer et al., 2011). These results
indicate a role for the LCE3 genes in psoriasis. The 32.4-kb
deleted region harbors, next to the LCE3B and LCE3C genes,
also a conserved noncoding element that functions as a
epidermal-specific enhancer (de Guzman Strong et al.,
2010). The loss of this enhancer in individuals harboring
LCE3C_LCE3B-del may function as a contributing factor in
psoriasis by affecting global transcription of the epidermal
differentiation complex genes.
The role of the LCE proteins in the formation of the CE has
not been extensively studied. In mice, Marshall et al. (2001)
found that members of the Lce protein family are expressed
rather late in epithelia, where they are cross-linked by
transglutaminases. By using immunoelectoron microscopy,
they demonstrated that an Lce1 member is a structural CE
component. Steinert et al. (2003) found that an LEP (now known
as LCE) is indeed cross-linked to involucrin and trichohyalin
in murine CEs. In humans, LCE2 protein expression was
restricted to the uppermost granular layer and the stratum
corneum, as shown by immunohistochemistry and immu-
noelectron microscopy (Bergboer et al., 2011). In murine
development, the expression of the Lce genes starts after the
expression of the Sprr genes, and is delayed until just before
initial formation of the barrier (Marshall et al., 2000).
We can only speculate on the role of the deletion of
LCE3B and LCE3C in the development of psoriasis. The
frequency of the deletion is also high in the general
population (about 60–70%), and is in fact more prevalent
than the undeleted allele. As the intact LCE3B and LCE3C
genes are ancestral and the deletion is a derived state, there
might be a possible evolutionary pressure to lose these genes.
As LCE3B and LCE3C are not normally expressed at
significant levels in skin, the situation is different from FLG
and atopic dermatitis. With respect to atopic dermatitis, it has
been suggested that a slightly leaky skin barrier could allow
penetration of microbial antigens and would favor natural
vaccination, thereby protecting against pathogens. In the case
of LCE3B and LCE3C, expression is only induced after barrier
disruption. Speculatively, incomplete barrier repair after
minor injury might lead to antigen penetration and natural
immunization against pathogens. The downside would be
that penetration of proinflammatory environmental stimuli
(e.g., Toll-like receptor ligands) would be favored as well,
which could trigger an inflammatory process that leads to
psoriasis. Such a scenario could also offer an explanation for
the Koebner phenomenon, which is observed inB25% of all
psoriasis patients (Weiss et al., 2002). In a recent study,
however, we did not find an association between LCE3C_
LCE3B-del and Koebner phenomenon in a Dutch cohort of
psoriasis patients (Bergboer et al., 2012a). When comparing
the reported population attributable risks for LCE3C_LCE3B-del
and psoriasis (23%) and FLG-null alleles and atopic dermatitis
(13%), it could be argued that skin barrier abnormalities are
as important (if not more) in psoriasis as they are for atopic
dermatitis.
Genetic interactions in psoriasis
Genetic polymorphisms that are considered as ‘‘disease-
causing’’ do not have the same effects in all individuals. For
example, HLA-C*06 is a very strong risk factor for psoriasis
(odds ratio 3–34, depending on the population (Riveira-
Munoz et al., 2011)), but the majority of HLA-C*06 carriers
do not have psoriasis. Additional causes for developing the
disease are environmental influences, epigenetic variation,
and genetic background. The dependence of a disease-
associated mutation or polymorphism on genetic background
is defined as ‘‘genetic interaction’’ or epistasis (Lehner, 2011).
When considering two loci that are associated with a disease,
a deviation from the additive effects of the two (either
negative or positive) is regarded as genetic interaction. The
molecular or cellular mechanism by which these two factors
exert their effect is then called ‘‘biological interaction’’.
Complex diseases are often regarded as interplay of many
interacting genetic factors and environmental stimuli. There
are, however, not many examples of genes that show proof of
epistasis in common complex disorders. Psoriasis is unique in
that sense, as recent publications have provided evidence for
genetic interaction between HLA-C*06 and LCE3C_LCE3B-
del, and between HLA-C*06 and ERAP1 (de Cid et al., 2009;
Strange et al., 2010; Riveira-Munoz et al., 2011; Zheng et al.,
2011). In one study, genetic interaction was observed
between three loci,HLA-C, CSTA, and D12346 (Vasilopoulos
et al., 2011). The interaction between HLA-C*06 and
LCE3C_LCE3B-del was first discovered in our Dutch psoriasis
case–control cohort but has now been documented for a
number of populations (see meta-analysis by Riveira-Munoz
et al. (2011)). Remarkably, this interaction was not found in a
few other populations with similar ethnic background.
Whether this reflects technical issues (genotyping by tagging
SNP or HLA-C*06 itself) or genetic heterogeneity remains to
be investigated. Previous studies have indicated substantial
differences in allele frequencies of LCE3C_LCE3B-del in
controls of European descent, which may have a role
(Riveira-Munoz et al., 2011). Similarly, FLG mutations asso-
ciated with atopic dermatitis, although widely replicated in
European and Asian populations, were not found in an Italian
cohort. The genetic interaction that we observed in our Dutch
cohort was particularly strong, as HLA-C*06 was only a risk
factor in the group that carried at least one deleted
LCE3C_LCE3B allele. Taken together, the combination of
HLA-C*06 positivity and a deleted LCE3C_LCE3B allele yielded
an odds ratio of 9.8 compared with HLA-C*06/LCE3C_LCE3B-
del-negative individuals as a reference category.
Interestingly, in a recent GWAS, the ERAP1 gene was
found to be a risk factor for psoriasis (Strange et al., 2010).
ERAP1 encodes a protease that has an important role in major
histocompatibility complex class I peptide processing. ERAP1
variants only influenced psoriasis susceptibility in individuals
carrying the HLA-C risk allele.
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On the basis of these genetic findings, it is a major
challenge to translate these data into meaningful biological
experiments, and to explain the observed epistasis in molec-
ular or cellular terms. In the next paragraph, we will discuss
the possible biological interactions that underlie the observed
genetic interactions between HLA-C*06 and its interacting
genes.
A model for the pathogenesis of psoriasis
Any model that tries to explain a disease should take clinical,
pharmacological, cell biological, and genetic data into
account. On the basis of genetic data, we propose that
candidate genes with a presumed or proven role in the
adaptive immune system are important. Table 1 lists all genes
with a presumed function in the adaptive immune system that
were found to be associated with psoriasis. The most
prominent genes from this list are HLA-C*06 and genes of
the IL-23 pathway, as these are the most widely replicated
genes. A second group of genetic risk factors listed in Table 1
are genes associated with innate immunity, such as the
b-defensins and genes associated with TNF-a and NF-kB-
regulated pathways such as TNIP1 and TNFAIP3. A third
functional category would be genes involved in physical skin
barrier maintenance, such as the LCE3B and LCE3C genes. In
Figure 3, we have tried to put these genetic factors into place,
in relation to biology and clinical data.
The epidermis is continuously exposed to mechanical
trauma and subclinical infections. Therefore, environmental
antigens and microbial components collectively named
pathogen-associated molecular patterns (PAMPs) will enter
the epidermis. These PAMPs can be derived from resident
commensal microorganisms, or from sources elsewhere in
the body (throat, gut, lungs). PAMPs can activate keratino-
cytes and immunocompetent cells via pattern recognition
receptors such as the Toll-like receptors, NOD-like receptors,
C-type lectin receptors, and RIGI-like helicases (Medzhitov,
2007; De Koning et al., 2010). These PAMPs activate the
epidermal innate immune system and drive expression and
secretion of antimicrobial proteins (defensins, SLPI, S100
proteins and LL-37) and chemokines/cytokines such as IL-8,
CXCL10, IL-1b, and TNF-a (De Koning et al., 2011). Minor
disturbances of the skin barrier will also initiate a repair
response, which includes upregulation of regular skin barrier
proteins (involucrin, transglutaminase-1) but will also induce
de novo expression of structural proteins putatively involved
in repair, regeneration, and temporal barrier recovery (e.g.,
keratins 6 and 17, SPRRs, SKALP/elafin, and members of the
LCE3 group). Under normal steady-state conditions, super-
ficial skin injury and exposure to PAMPs will quickly lead to
keratinocyte activation, elimination of infectious agents,
barrier repair, and restoration of homeostasis. In genetically
predisposed individuals, minor injury and exposure to PAMPs
Trauma, infection
Increased penetration of exogenous molecules
Environmental antigens,
microbial components
Barrier disruption,
cell damage, and
keratinocyte activation
Barrier repair, dependent
on LCE3B/C del status
Activation of innate immunity:
chemokines, defensins, TNIP1, TNFAIP3
TNF-α, IL-1, IL-17,
IL-22, IFNs
Chemotaxis of
immunocompetent cells
Activation of adaptive immunity:
HLA-Cw6, IL-12B, IL-23
T
T
T
T
T
T
T
T
TT
Figure 3. Tentative model of psoriasis based on genetic and cell biological data. Polymorphisms of genes involved in skin barrier and immune function will
cooperatively determine the exposure, handling, and response to environmental stimuli (pathogen-associated molecular patterns, antigens). Depending on the
host genotype, this may lead to increased penetration of antigens, low-grade inflammation caused by keratinocyte activation, and chemotaxis of
immunocompetent cells. Ultimately, this could lead to activation of adaptive immunity in genetically predisposed individuals who respond to hitherto
unidentified external antigens or autoantigens through molecular mimicry. The ensuing (HLA-Cw6-restricted) immune response, which includes secretion of
Th1 and Th17 cytokines, will in turn cause activation of keratinocytes, resulting in a vicious cycle and chronicity of inflammation. Reprinted from Bergboer et al.
(2011), with permission from Elsevier.
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and cytokines could lead to enhanced inflammatory
responses (Zeeuwen et al., 2008), increased production of
b-defensins in individuals with high copy numbers (Jansen
et al., 2009), and insufficient or delayed skin barrier repair
in individuals who are heterozygous or homozygous for
LCE3C_LCE3B-del (de Cid et al., 2009; Bergboer et al., 2011).
This will affect the innate and adaptive immune system in
several ways. First, the secretion of mediators such as IL-8,
CXCL10, and b-defensins will attract neutrophils, T cells, and
dendritic cells to the epidermal compartment. Second,
incomplete barrier repair will allow sustained penetration of
PAMPs or even larger (protein) antigens that will be taken up
by Langerhans cells and dendritic cells and presented to
T cells. At this point, T-cell activation will be initiated, which
could be facilitated by genetic predispositions such as HLA-
C*06 or polymorphisms in genes of the IL-23 pathway and
other factors mentioned above. The observed epistatic
interaction between LCE3C_LCE3B-del and HLA-C*06 could
be explained in the context of such a mechanism. Sustained
penetration of protein antigens with HLA-Cw6-restricted
immunodominant epitopes could cause antigen-specific
activation of CD8þ T cells, leading to secretion of TNF-a
and IFN-g. This is compatible with the TNF-a and IFN-g
keratinocyte gene expression signature found in psoriatic
epidermis. In a similar way, the observed epistasis of HLA-
C*06 and ERAP1 can be explained by preferred trimming of
immunogenic HLA-Cw6-restricted peptides from relevant
antigens by the ERAP1 protease. So far, no T cells specific
for a defined HLA-Cw6-restricted peptide have ever been
identified in psoriasis. It is therefore not clear whether a
regular adaptive immune response to foreign proteins is
relevant in this disease. Similarly, no convincing evidence for
an autoreactive response has been obtained so far. Assuming
that HLA-C*06 is the true causative gene of PSORS1, it
remains to be proven whether HLA-Cw6 is a classical major
histocompatibility complex allele involved in presentation of
self-peptides, or crosspresentation of nonself peptides, lead-
ing to (cross)priming of T cells. Similarly, a role of HLA-
Cw6 in the interaction with natural killer cells via killer Ig
receptors cannot be ruled out.
Whatever the mechanism of T-cell activation may be,
either antigen-driven or not, large numbers of activated
CD4þ and CD8þ cells are present in the lesion. CD8þ
cells in particular also invade the epidermis and are in close
contact with keratinocytes and Langerhans cells. These
activated T cells will secrete Th1 and Th17 cytokines (IFN-
g, TNF-a IL-17, IL-23, IL-22), which will further activate the
keratinocytes. IFN-g and Th17 cytokines will also synergize
with IL-1 and TNF-a, e.g., derived from keratinocytes, to
further enhance expression of antimicrobial proteins and
chemokines by keratinocytes. This scenario creates a vicious
circle: activated keratinocytes produce chemokines and
antimicrobial proteins that attract immunocompetent cells.
Keratinocytes will continue to proliferate, and differentiate
incompletely, thereby expressing genes that make a provi-
sional skin barrier, which may be inferior in individuals
carrying heterozygous or homozygous deletions of the LCE3B
and LCE3C genes. At the same time, the expression of some
genes involved in normal cornification (e.g., filaggrin and
loricrin) is suppressed. The resulting incomplete barrier of
lesional psoriatic skin will continuously allow PAMPs and
protein antigens to enter the skin and activate immunocom-
petent cells. As there is no negative feedback in the process
once initiated (depicted in Figure 3), this could explain the
chronicity of a lesion.
From the scheme in Figure 3, it is also evident that the
vicious circle can be interrupted at any point, using the
appropriate medication. T-cell-directed therapies will sup-
press secretion of Th1 and Th17 cytokines, resulting in a
decrease of keratinocyte activation and a concomitant
suppression of keratinocyte-derived chemokine secretion.
Anti-TNF will act on secreted or membrane-bound TNF,
either from keratinocytes or from immunocytes, and has
indeed proven to be an effective therapy (Lowes et al., 2007).
Retinoids suppress cytokine-induced keratinocyte activation
and will decrease defensin and cytokine secretion (Tjabringa
et al., 2008). Vitamin D3 derivatives will inhibit keratinocyte
proliferation (Gniadecki, 1997) and thereby normalize
epidermal differentiation, promoting skin barrier restoration.
In addition, both retinoids and vitamin D3 derivatives may
also act on the immune system by stimulating the expansion
of regulatory T cells or suppressing Th17 function (Mucida
et al., 2007; Ghoreishi et al., 2009). Various other successful
antipsoriatic therapies such as corticosteroids, dithranol, and
methotrexate may act on many points in the vicious circle, as
they are found to be immunosuppressive but can also affect
keratinocyte proliferation and differentiation (Gottlieb et al.,
1992; Schwartz et al., 1992). Even the observed moderately
beneficial effects of skin occlusion as a monotherapy could
be explained by decreasing the exposure to exogenous
stimuli using an artificial skin barrier (Gottlieb et al., 1990).
CONCLUDING REMARKS
In summary, there are now more than 25 psoriasis risk genes
known, and two of them (HLA-C*06 and LCE3C_LCE3B-del)
contribute a significant proportion of the population attribu-
table risk. At least three different biological pathways
(adaptive immunity, innate immunity, and skin barrier) are
known to be involved, and their potential mode of genetic
and biological interaction is illustrated in Figure 3. We
believe that this model generates testable hypotheses, which
may uncover the pathobiological mechanisms of psoriasis,
and could contribute to prevention and therapy for psoriasis.
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